SDX 7320

Drug Profile

SDX 7320

Alternative Names: SDX-7320

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SynDevRx, Inc
  • Class Antineoplastics; Cyclohexanes; Drug conjugates; Sesquiterpenes; Unsaturated fatty acids
  • Mechanism of Action DNA synthesis inhibitors; Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Breast cancer; Colorectal cancer; Unspecified

Most Recent Events

  • 26 Jul 2018 SynDevRx has patents related to SDX 7320, in USA and China, with applications pending in other countries (SynDevRx website, July 2018)
  • 26 Jul 2018 Preclinical trials in Breast cancer (Metastatic disease) in USA (unspecified route) (SynDevRx pipeline, July 2018)
  • 26 Jul 2018 Preclinical trials in Colorectal cancer (Metastatic disease) in USA (unspecified route) (SynDevRx pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top